Nasdaq rxrx.

Find the latest news headlines from Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. Twist Bioscience (NASDAQ: TWST), like RXRX, is a genomics stock positioned to win no matter which companies capture the largest market share.TWST creates synthetic DNA, which is critical to early ...Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) 45% Price Boost Is Out Of Tune With Revenues Dec 09. Co-Founder notifies of intention to sell stock Dec 08. Chief Financial Officer exercised options and sold US$266k worth of stock Nov 19. Consensus EPS estimates fall by 18% Nov 16.Find the latest historical data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.2013. 550. Chris Gibson. https://www.recursion.com. Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which ...

Recursion Pharmaceuticals (NASDAQ: RXRX) has witnessed quite a roller-coaster year. A resounding investment of $50 million from tech titan Nvidia (NASDAQ: NVDA) in July rocketed its shares.

Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...

Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.38 per share a year ago.RXRX | Complete Recursion Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Jan 21, 2024 · Platinum Investment Management Ltd. lessened its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 13.9% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,335,132 shares of the compa Real time Recursion Pharmaceuticals (RXRX) stock price quote, stock graph, news & analysis.Although the biotech company missed revenue consensus, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) saw a 150% increase in revenue in the third quarter to $2.5 million in Q3 2021, up from $1 ...

Recursion Pharmaceuticals (RXRX) Stock Forecast & Price TargetStrong Buy 3 Ratings 3 Buy 0 Hold 0 Sell Based on 3 analysts giving stock ratings to Recursion Pharmaceuticals in the past 3 months RXRX Stock 12 Months Forecast $48.67 (32.67% Upside) Based on 3 Wall Street analysts offering 12 month price targets for Recursion Pharmaceuticals in …

114% vs Avg 9.70 Day Range 10.68 4.54 52 Week Range 16.75 Partner Center Your Watchlists Customize MarketWatch Have Watchlists? Log in to see them here or sign …

RECURSION PHARMACEUTICALS INC ( RXRX) is a small-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 43% based on the firm’s underlying fundamentals and the ...Shafique Virani, Chief Business Officer of Recursion Pharmaceuticals Inc (NASDAQ:RXRX), sold 18,000 shares of the company on January 16, 2024, according to a recent SEC Filing ... Biotech firm Recursion (NASDAQ:RXRX) said on Wednesday that it had secured a $50M investment from Nvidia , which was implemented as a private investment in public equity. RXRX shares jump +72.7% ...N/A Dividend Yield N/A Price Target $11.20 Stock Analysis Analyst Forecasts Chart Competitors Earnings Financials Headlines Insider Trades Ownership SEC Filings …Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...After announcing that it would get a $50 million investment from NVIDIA ( NVDA 0.27%) on July 12, Recursion Pharmaceuticals ( RXRX 8.83%) saw its stock blast off, rising 87% over the following two ...Find the latest historical data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.

Data is delayed at least 15 minutes. Nasdaq.com will report pre-market and after hours trades. Pre-Market trade data will be posted from 4:15 a.m. ET to 7:30 a.m. ET of the …Nov 22, 2023 · That's what's happening with Recursion Pharmaceuticals ( RXRX 4.83%), an innovative biotech. The company's shares are currently changing hands for $7.07 apiece, but the consensus one-year target ... NASDAQ:RXRX opened at $9.78 on Friday. Recursion Pharmaceuticals has a 1 year low of $4.54 and a 1 year high of $16.75. The stock has a market cap of $2.12 billion, a price-to-earnings ratio of -6.70 and a beta of 0.63.Oct 14, 2021 · The big shareholder groups in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) have power over the company. Institutions often own shares in more established companies, while it's not unusual to see ... May 8, 2023 · Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.34 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.33 per share a year ago. These figures are ... Find the latest Financials data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. Jul 6, 2023 · Fintel reports that on July 12, 2023, Needham reiterated coverage of Recursion Pharmaceuticals Inc - (NASDAQ:RXRX) with a Buy recommendation.. Analyst Price Forecast Suggests 117.07% Upside. As of ...

Welcome to Recursion: The Future of TechBio. LEARN HOW ›. NEWS: Recursion unveils LOWE, an LLM-Orchestrated Workflow Engine for drug discovery. Decoding Biology To Radically Improve Lives. Explore Our Story: We are leveraging new technology to create virtuous cycles of learning around datasets to build a next-generation biopharmaceutical company. Cathie Wood can't get enough of Recursion Pharmaceuticals (RXRX-1.25%) stock. Through her Ark Innovation ETF, the maverick growth stock portfolio manager bought shares of the biotech three times ...

November 10, 2023 at 5:06 AM · 3 min read. With a price-to-sales (or "P/S") ratio of 23.8x Recursion Pharmaceuticals, Inc. ( NASDAQ:RXRX) may be sending very bearish signals at the moment, given ...Sep 14, 2023 · Recursion Pharmaceuticals (NASDAQ:RXRX) was a new buy in the portfolio last week. This is a clinical-stage biotechnology company that combines experimental biology, bioinformatics, and artificial ... Nasdaq. 15,415.02 +104.05 (+0.68%) ... Investors in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) have tasted that bitter downside in the last year, as the share price dropped 20%. That's ...Twist Bioscience (NASDAQ: TWST), like RXRX, is a genomics stock positioned to win no matter which companies capture the largest market share. TWST creates synthetic DNA, ...Recursion Pharmaceuticals ( NASDAQ: RXRX) - the subject of this analysis - IPOd in April 2021, issuing 27.88m shares at a price of $18 per share, and raising >$500m - making it the sixth largest ...With a relentless focus on transforming the biotechnology landscape through its artificial intelligence (AI) and machine learning (ML) driven platform, Recursion Pharmaceuticals (NASDAQ:RXRX ...The NASDAQ 100 After Hours Indicator is down -8.22 to 16,769.18. The total After hours volume is currently 64,637,594 shares traded.The following are the most active stocks for the after hours ...

4. Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best and most notable AI healthcare stocks to buy. The Utah-based Recursion ...

Dec 22, 2023 · The NASDAQ 100 After Hours Indicator is down -8.22 to 16,769.18. The total After hours volume is currently 64,637,594 shares traded.The following are the most active stocks for the after hours ...

Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ...Health Care Sector Update for 01/04/2024: SEM, XERS, RXRX, OMGA, NVO January 04, 2024 — 03:53 pm EST Written by MT Newswires for MTNewswires ->Jan 21, 2024 · Platinum Investment Management Ltd. lessened its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 13.9% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,335,132 shares of the compa SAN FRANCISCO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today presented a ...So should Recursion Pharmaceuticals (NASDAQ:RXRX) shareholders be worried about its cash burn? In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of ...Nov 21, 2023 · Cathie Wood can't get enough of Recursion Pharmaceuticals (RXRX-3.13%) stock. Through her Ark Innovation ETF, the maverick growth stock portfolio manager bought shares of the biotech three times ... SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to …Nov 15, 2023 · AI-driven drug discovery firm Recursion Pharmaceuticals (NASDAQ:RXRX) added ~17% on Wednesday after ARK Innovation ETF (NYSEARCA:ARKK), managed by famous stock picker Cathie Wood, bought ~3.8M of ... Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 1.9% on Insider Selling marketbeat.com - December 29 at 10:20 AM: Blake Borgeson Sells 20,054 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock marketbeat.com - December 28 at 6:33 PMNASDAQ:RXRX opened at $9.78 on Friday. Recursion Pharmaceuticals has a 1 year low of $4.54 and a 1 year high of $16.75. The stock has a market cap of $2.12 billion, a price-to-earnings ratio of -6 ...Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) 45% Price Boost Is Out Of Tune With Revenues Dec 09. Co-Founder notifies of intention to sell stock Dec 08. Chief Financial Officer exercised options and sold US$266k worth of stock Nov 19. Consensus EPS estimates fall by 18% Nov 16.Dec 16, 2023 · Recursion Pharmaceuticals (NASDAQ: RXRX) has built one of the world’s most advanced AI-powered platforms to help decode human biology. RXRX gathers data and experiments on millions of biological ...

On October 25, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) announced that it has entered into a stock purchase agreement for the sale of approximately 15.3 million units of its common stock in a ...So should Recursion Pharmaceuticals (NASDAQ:RXRX) shareholders be worried about its cash burn? In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of ...Sep 14, 2023 · Recursion Pharmaceuticals (NASDAQ:RXRX) was a new buy in the portfolio last week. This is a clinical-stage biotechnology company that combines experimental biology, bioinformatics, and artificial ... Feb 28, 2023 · Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.38 per share a year ago. Instagram:https://instagram. green bay press gazette obituaries facebookgenie gs 1930 battery charger troubleshootingtrackerhistorie Shares of Recursion Pharmaceuticals (RXRX-2.63%) were skyrocketing 82% higher this week as of the market close on Thursday, according to data provided by S&P Global Market Intelligence. ge microwave ownerpercent27s manualfylmhay aytalyayy bdwn sanswr zyrnwys farsy 2 days ago · Director Blake Borgeson of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) has sold 20,054 shares of the company on January 23, 2024, according to a recent SEC Filing. The transaction was executed at ... sksi Data is delayed at least 15 minutes. Nasdaq.com will report pre-market and after hours trades. Pre-Market trade data will be posted from 4:15 a.m. ET to 7:30 a.m. ET of the …Find the latest on short interest for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.